Milpran Use In Pregnancy & Lactation

Be advised if patient is pregnant or breast-feeding, thinks she may be pregnant or is planning to have a baby before prescribing this medicine.
Pregnancy: It is not recommended to take this medicine if patient is a woman of childbearing potential not using contraception and during pregnancy. Advise patient to consult a doctor if she discovers that she is pregnant during treatment, to decide whether or not treatment should be continued.
If patient is taking Milpran until delivery, the baby could present immediately or soon after delivery reversible symptoms linked to a withdrawal syndrome or exposure to milnacipran. In that case, a clinical surveillance should be performed.
Advise patient to ask the doctor or pharmacist before taking any medicines.
Observational data indicate an increased risk (less than 2-fold) of postpartum haemorrhage following SSRIs/SNRIs exposure within the month prior to birth. If patient takes Milpran near the end of pregnancy there may be an increased risk of heavy vaginal bleeding shortly after birth, especially if the patient has a history of bleeding disorders. Be aware if patient is taking Milpran.
Breast-feeding: This medicine may pass in the mother's milk. Therefore, breast-feeding is contraindicated. Advise patient to ask the doctor or pharmacist before taking any medicines.
Fertility: Animal fertility is affected by Milnacipran.
There is no available data on impact of Milnacipran on human fertility.